Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration

CRISPR-Cas13 systems have therapeutic promise for the precise correction of point mutations in RNA. Using adenosine deaminase acting on RNA (ADAR) effectors, A-I base conversions can be targeted using guide RNAs (gRNAs). We compare the Cas13 effectors PspCas13b and Cas13bt3 for the repair of the gen...

Full description

Bibliographic Details
Main Authors: Fry, LE, Major, L, Salman, A, McDermott, LA, Yang, J, King, AJ, McClements, ME, MacLaren, RE
Format: Journal article
Language:English
Published: Nature Research 2025
_version_ 1824459189202714624
author Fry, LE
Major, L
Salman, A
McDermott, LA
Yang, J
King, AJ
McClements, ME
MacLaren, RE
author_facet Fry, LE
Major, L
Salman, A
McDermott, LA
Yang, J
King, AJ
McClements, ME
MacLaren, RE
author_sort Fry, LE
collection OXFORD
description CRISPR-Cas13 systems have therapeutic promise for the precise correction of point mutations in RNA. Using adenosine deaminase acting on RNA (ADAR) effectors, A-I base conversions can be targeted using guide RNAs (gRNAs). We compare the Cas13 effectors PspCas13b and Cas13bt3 for the repair of the gene USH2A, a common cause of inherited retinal disease and Usher syndrome. In cultured cells, we demonstrate up to 80% efficiency for the repair of the common c.11864 G > A and its murine equivalent c.11840 G > A, across different gRNAs and promoters. We develop and characterize a mouse model of Usher syndrome carrying the c.11840 G > A mutation designed for the evaluation of base editors for inherited retinal disease. Finally, we compare Cas13 effectors delivered via AAV for the repair of Ush2a in photoreceptors. Mean RNA editing rates in photoreceptors across different constructs ranged from 0.32% to 2.04%, with greater efficiency in those injected with PspCas13b compared to Cas13bt3 constructs. In mice injected with PspCas13b constructs, usherin protein was successfully restored and correctly localized to the connecting cilium following RNA editing. These results support the development of transcriptome targeting gene editing therapies for retinal disease.
first_indexed 2025-02-19T04:37:50Z
format Journal article
id oxford-uuid:5cae6be7-8b7d-48aa-b8f4-92d7dd50ec17
institution University of Oxford
language English
last_indexed 2025-02-19T04:37:50Z
publishDate 2025
publisher Nature Research
record_format dspace
spelling oxford-uuid:5cae6be7-8b7d-48aa-b8f4-92d7dd50ec172025-02-08T20:15:31ZComparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degenerationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5cae6be7-8b7d-48aa-b8f4-92d7dd50ec17EnglishJisc Publications RouterNature Research2025Fry, LEMajor, LSalman, AMcDermott, LAYang, JKing, AJMcClements, MEMacLaren, RECRISPR-Cas13 systems have therapeutic promise for the precise correction of point mutations in RNA. Using adenosine deaminase acting on RNA (ADAR) effectors, A-I base conversions can be targeted using guide RNAs (gRNAs). We compare the Cas13 effectors PspCas13b and Cas13bt3 for the repair of the gene USH2A, a common cause of inherited retinal disease and Usher syndrome. In cultured cells, we demonstrate up to 80% efficiency for the repair of the common c.11864 G > A and its murine equivalent c.11840 G > A, across different gRNAs and promoters. We develop and characterize a mouse model of Usher syndrome carrying the c.11840 G > A mutation designed for the evaluation of base editors for inherited retinal disease. Finally, we compare Cas13 effectors delivered via AAV for the repair of Ush2a in photoreceptors. Mean RNA editing rates in photoreceptors across different constructs ranged from 0.32% to 2.04%, with greater efficiency in those injected with PspCas13b compared to Cas13bt3 constructs. In mice injected with PspCas13b constructs, usherin protein was successfully restored and correctly localized to the connecting cilium following RNA editing. These results support the development of transcriptome targeting gene editing therapies for retinal disease.
spellingShingle Fry, LE
Major, L
Salman, A
McDermott, LA
Yang, J
King, AJ
McClements, ME
MacLaren, RE
Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration
title Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration
title_full Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration
title_fullStr Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration
title_full_unstemmed Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration
title_short Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration
title_sort comparison of crispr cas13b rna base editing approaches for ush2a associated inherited retinal degeneration
work_keys_str_mv AT fryle comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration
AT majorl comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration
AT salmana comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration
AT mcdermottla comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration
AT yangj comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration
AT kingaj comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration
AT mcclementsme comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration
AT maclarenre comparisonofcrisprcas13brnabaseeditingapproachesforush2aassociatedinheritedretinaldegeneration